Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06925269 · ClinicalTrials.gov registry record
DMD Voice: Qualitative Interviews With Patients and Caregivers
A clinical trial of Duchenne Muscular Dystrophy (DMD), sponsored by Red Nucleus Enterprise Solutions.
- Recruiting
- Registry status
- 68
- Enrollment target
- 1
- Study location
NCT06925269: Recruiting study of Duchenne Muscular Dystrophy (DMD), sponsored by Red Nucleus Enterprise Solutions.
NCT06925269 is a study of Duchenne Muscular Dystrophy (DMD) that is actively recruiting participants, run by Red Nucleus Enterprise Solutions. The registered enrollment target is 68 participants, below the 81-participant average among 3 other Duchenne Muscular Dystrophy (DMD) trials with a reported enrollment target (16% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06925269, a study of Duchenne Muscular Dystrophy (DMD), is actively recruiting participants, sponsored by Red Nucleus Enterprise Solutions.
- RECRUITING
- Registry status
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand DMD functional losses or abilities and their association with independence and quality of life from the perspective of individuals with DMD and/or and their caregivers. This is a qualitative interview study in which individuals with DMD and/or their caregivers will be asked to participate in a semi-structured, approximately 60- minute interview. Interviews will focus on functional abilities and independence. Caregivers and boys with DMD will be interviewed. This study includes no treatment nor intervention; however, some participants are being treated by a drug that is approved in the U.S. and the U.K. and under investigation in other geographies.
Primary Outcome
Participants will participate in a semi-structured interview
Conditions Studied
Study Locations (1)
Pennsylvania
- Red Nucleus - Yardley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2026-12 |
What NCT06925269 shows while recruiting
NCT06925269 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 81-participant average among 3 other Duchenne Muscular Dystrophy (DMD) trials with a reported enrollment target (16% lower).
The record links to 1 condition, with Duchenne Muscular Dystrophy (DMD) appearing as the primary indexed condition, and to 0 interventions.
NCT06925269 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06925269 about?
NCT06925269 is a clinical study titled "DMD Voice: Qualitative Interviews With Patients and Caregivers". The purpose of this study is to understand DMD functional losses or abilities and their association with independence and quality of life from the perspective of individuals with DMD and/or and their caregivers. This is a qualitative interview study in which individuals with DMD and/or their caregi...
What is the current status of trial NCT06925269?
This trial is currently recruiting. The enrollment target is 68 participants. The study started on 2025-03-31. Estimated completion is 2026-12.
What conditions does trial NCT06925269 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy (DMD).
Who is sponsoring clinical trial NCT06925269?
This trial is sponsored by Red Nucleus Enterprise Solutions, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06925269 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy (DMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
RECRUITING
-
Urinary Titin Biomarker in DMD
RECRUITING · NA
-
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI